On 22 January 2025, Johnson & Johnson (J&J) reported its results for Q4 2024, which saw sales growth of 5.3% to $22.5B.
On the same day, Genmab announced that worldwide annual net sales of Darzalex® (daratumumab) for 2024, as reported by J&J, totalled USD11.7 billion. US sales accounted for more than half of this total, reaching USD6.6 billion. Genmab receives royalties on the worldwide net sales of Darzalex® (IV and SC), under its exclusive worldwide licence to Janssen to develop, manufacture and commercialise daratumumab.
J&J reports that it achieved several significant regulatory milestones in Q4 2024 across the EU and US. This includes the European approval for several new indications of J&J biologics, such as Darzalex® SC based quadruplet regimen for multiple myeloma (October 2024), and Rybrevant® (amivantamab) in combination with Lazcluze® (lazertinib) for non-small cell lung cancer (December 2024). J&J also submitted an application in the EU for approval of Darzalex® SC for high-risk smouldering multiple myeloma (November 2024).
In the US, J&J submitted an application for approval of a new indication of Darzalex Faspro® (daratumumab and hyaluronidase-hj) for high-risk smouldering multiple myeloma (November 2024), and received Breakthrough Therapy designation (BTD) for nipocalimab for the treatment of adults living with moderate-to-severe Sjögren’s disease (November 2024). J&J also sought FDA approval for a subcutaneous induction regimen of Tremfya® (guselkumab) for ulcerative colitis (November 2024).